Revance Stock Today
| RVNC Stock | USD 3.64 0.01 0.27% |
Performance0 of 100
| Odds Of DistressOver 81
|
Revance is trading at 3.64 as of the 31st of January 2025, a 0.27 percent decrease since the beginning of the trading day. The stock's open price was 3.65. Revance has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Note, on November 2, 2023, Senator Thomas R Carper of US Senate acquired under $15k worth of Revance's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date | Category Healthcare | Classification Health Care |
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. Revance Therapeutics, Inc. The company has 104.39 M outstanding shares of which 4.51 M shares are at this time shorted by private and institutional investors with about 1.7 trading days to cover. More on Revance
Moving together with Revance Stock
Moving against Revance Stock
| 0.54 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
| 0.47 | MLAB | Mesa Laboratories Earnings Call This Week | PairCorr |
| 0.34 | GILD | Gilead Sciences Earnings Call This Week | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Revance Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Mark Foley | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRevance can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Revance's financial leverage. It provides some insight into what part of Revance's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revance (RVNC) is traded on NASDAQ Exchange in USA. It is located in 1222 Demonbreun Street, Nashville, TN, United States, 37203 and employs 597 people. Revance is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 378.94 M. Revance conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 104.39 M outstanding shares of which 4.51 M shares are at this time shorted by private and institutional investors with about 1.7 trading days to cover.
Revance currently holds about 233.82 M in cash with (216.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.2.
Check Revance Probability Of Bankruptcy
Ownership AllocationRevance owns a total of 104.39 Million outstanding shares. The majority of Revance outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Revance to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Revance. Please pay attention to any change in the institutional holdings of Revance as this could imply that something significant has changed or is about to change at the company. On November 2, 2023, Senator Thomas R Carper of US Senate acquired under $15k worth of Revance's common stock.
Check Revance Ownership Details
Revance Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 2.3 M | |
| Lmr Partners Llp | 2024-09-30 | 2.2 M | |
| D. E. Shaw & Co Lp | 2024-09-30 | 1.9 M | |
| Qube Research & Technologies | 2024-09-30 | 1.9 M | |
| Omni Event Management Ltd | 2024-09-30 | 1.7 M | |
| Palo Alto Investors, Llc | 2024-09-30 | 1.6 M | |
| Cnh Partners, Llc | 2024-09-30 | 1.4 M | |
| Madison Avenue Partners, Lp | 2024-09-30 | 1.4 M | |
| Hsbc Holdings Plc | 2024-09-30 | 1.2 M | |
| Blackrock Inc | 2024-09-30 | 8.7 M | |
| Vanguard Group Inc | 2024-09-30 | 5.7 M |
Revance Historical Income Statement
Revance Stock Against Markets
Revance Corporate Management
| Dwight JD | Chief Counsel | Profile | |
| Conor Gallagher | Head Aesthetics | Profile | |
| Erica Jordan | Chief Officer | Profile | |
| Azita Nejad | VP Operations | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revance. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Revance Stock refer to our How to Trade Revance Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revance. If investors know Revance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revance listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.34) | Revenue Per Share | Quarterly Revenue Growth 0.107 | Return On Assets | Return On Equity |
The market value of Revance is measured differently than its book value, which is the value of Revance that is recorded on the company's balance sheet. Investors also form their own opinion of Revance's value that differs from its market value or its book value, called intrinsic value, which is Revance's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revance's market value can be influenced by many factors that don't directly affect Revance's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revance's value and its price as these two are different measures arrived at by different means. Investors typically determine if Revance is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revance's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.